Travere Therapeutics, Inc.

NASDAQ:TVTX

18.71 (USD) • At close January 6, 2025
Bedrijfsnaam Travere Therapeutics, Inc.
Symbool TVTX
Munteenheid USD
Prijs 18.71
Beurswaarde 1,628,411,753
Dividendpercentage 0%
52-weken bereik 5.12 - 20.33
Industrie Biotechnology
Sector Healthcare
CEO Dr. Eric M. Dube Ph.D.
Website https://www.travere.com

An error occurred while fetching data.

Over Travere Therapeutics, Inc.

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric

Vergelijkbare Aandelen

Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc.

XENE

40.72 USD

Krystal Biotech, Inc. logo

Krystal Biotech, Inc.

KRYS

155.81 USD

ImmunityBio, Inc. logo

ImmunityBio, Inc.

IBRX

2.76 USD

Establishment Labs Holdings Inc. logo

Establishment Labs Holdings Inc.

ESTA

46.65 USD

Addus HomeCare Corporation logo

Addus HomeCare Corporation

ADUS

125.7 USD

Ligand Pharmaceuticals Incorporated logo

Ligand Pharmaceuticals Incorporated

LGND

107.92 USD

Dynavax Technologies Corporation logo

Dynavax Technologies Corporation

DVAX

12.76 USD

Supernus Pharmaceuticals, Inc. logo

Supernus Pharmaceuticals, Inc.

SUPN

37.05 USD

ModivCare Inc. logo

ModivCare Inc.

MODV

11.67 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)